{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T22:21:15Z","timestamp":1770675675564,"version":"3.49.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the epidemiological characteristics of immune-mediated neuropathies (primarily including Guillain-Barr\u00e9 Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy) and systematically analyze their associated risk factors, providing a theoretical basis for disease prevention and early intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was conducted. 158 patients with immune-mediated neuropathies admitted to our hospital between January 2020 and December 2023 were selected as the case group, while 160 healthy individuals undergoing physical examinations during the same period were selected as the control group. Demographic data and clinical records (including history of preceding infections, vaccination history, history of comorbid diseases, etc.) were collected and compared for all subjects. Univariate analysis and multivariate logistic regression analysis were used to identify independent risk factors for immune-mediated neuropathies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The annual incidence of immune-mediated neuropathies was 1.24 per 100,000, with a bimodal age distribution (20\u201330\u202fyears and 50\u201370\u202fyears). The incidence was slightly higher in males than in females (1.5:1). Univariate analysis showed statistically significant differences (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.05) between the case and control groups in terms of history of preceding infection (particularly respiratory and gastrointestinal infections), recent vaccination history, history of surgical trauma, and comorbid autoimmune diseases. Multivariate logistic regression analysis further confirmed that preceding\n                      <jats:italic>Campylobacter jejuni<\/jats:italic>\n                      infection (OR\u202f=\u202f4.52, 95% CI: 2.81\u20137.26,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.000), Cytomegalovirus infection (OR\u202f=\u202f3.18, 95% CI: 1.95\u20135.19,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.000), recent surgical trauma (OR\u202f=\u202f2.45, 95% CI: 1.40\u20134.29,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.002), and the presence of an underlying autoimmune disease (OR\u202f=\u202f2.90, 95% CI: 1.72\u20134.89,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.000) were independent risk factors for the onset of immune-mediated neuropathies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The onset of immune-mediated neuropathies is closely related to various environmental and individual factors. Preceding infections (especially\n                      <jats:italic>Campylobacter jejuni<\/jats:italic>\n                      and Cytomegalovirus) are the most significant independent risk factors. In clinical practice, high suspicion for immune-mediated neuropathies should be maintained for individuals with the aforementioned risk factors who present with neurological symptoms, to achieve early diagnosis and treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1733557","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:22:49Z","timestamp":1770614569000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of the incidence status and risk factors for immune-mediated neuropathies: a single-center case\u2013control study"],"prefix":"10.3389","volume":"17","author":[{"given":"Yunlong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanchang","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingxiu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengchao","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Outpatient, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"7288","DOI":"10.3390\/ijms24087288","article-title":"Immune-mediated neuropathies: pathophysiology and management","volume":"24","author":"Shastri","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/S0140-6736(25)00414-3","article-title":"Guillain-Barre syndrome outbreak in Pune: a health emergency","volume":"405","author":"Banerjee","year":"2025","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00415-025-13216-8","article-title":"Genetic variation of low-to-medium-affinity fc-gamma receptors in Guillain-Barr\u00e9 syndrome","volume":"272","author":"van Tilburg","year":"2025","journal-title":"J Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-023-01776-0","article-title":"Molecular mimicry and cancer vaccine development","volume":"22","author":"Tagliamonte","year":"2023","journal-title":"Mol Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/jnnp-2025-336046","article-title":"Neurofilament light chain improves clinical prognostic models for Guillain-Barre syndrome","volume":"96","author":"Thomma","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10654-019-00596-1","article-title":"Vaccines and the risk of Guillain-Barre syndrome","volume":"35","author":"Chen","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e13021","DOI":"10.1111\/tid.13021","article-title":"Guillain-Barre syndrome post renal transplant: a systematic review","volume":"21","author":"Ostman","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1212\/WNL.0b013e3181cff735","article-title":"Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh","volume":"74","author":"Islam","year":"2010","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barre syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.bbmt.2019.04.021","article-title":"Incidence, risk factors, and outcome of immune-mediated neuropathies (IMNs) following haploidentical hematopoietic stem cell transplantation","volume":"25","author":"Ren","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/mus.27708","article-title":"Diagnosis of chronic inflammatory demyelinating polyneuropathy","volume":"66","author":"Allen","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1007\/s11033-023-08389-2","article-title":"Molecular mimicry of host short linear motif-mediated interactions utilised by viruses for entry","volume":"50","author":"Goswami","year":"2023","journal-title":"Mol Biol Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barre syndrome and fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barre syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1021\/acschemneuro.6b00042","article-title":"The immune system and neuroinflammation as potential sources of blood-based biomarkers for Alzheimer's disease, Parkinson's disease, and Huntington's disease","volume":"7","author":"Clark","year":"2016","journal-title":"ACS Chem Neurosci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"9398","DOI":"10.3390\/ijms26199398","article-title":"Monoclonal antibodies as therapeutic agents in autoimmune and neurodegenerative diseases of the central nervous system: current evidence on molecular mechanisms and future directions","volume":"26","author":"Skarlis","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1228282","DOI":"10.3389\/fncel.2023.1228282","article-title":"Research progress on the reduced neural repair ability of aging Schwann cells","volume":"17","author":"Zhang","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12031-020-01634-4","article-title":"Increased levels of IL-34 in acquired immune-mediated neuropathies","volume":"71","author":"Rezaei","year":"2021","journal-title":"J Mol Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41564-018-0133-7","article-title":"Campylobacter jejuni transcriptional and genetic adaptation during human infection","volume":"3","author":"Crofts","year":"2018","journal-title":"Nat Microbiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1080\/21645515.2021.1985890","article-title":"Risk of Guillain-Barre syndrome following herpes zoster, United States, 2010-2018","volume":"17","author":"Anderson","year":"2021","journal-title":"Hum Vaccin Immunother"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1733557\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:22:50Z","timestamp":1770614570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1733557\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":22,"alternative-id":["10.3389\/fneur.2026.1733557"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1733557","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"article-number":"1733557"}}